Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Genentech/Novartis Ophthalmics' Lucentis (ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, will dominate the market and will become the new standard of care in the treatment of wet age-related macular degeneration (AMD) by 2015.

The new Pharmacor report entitled Age-Related Macular Degeneration finds that Lucentis will dominate the wet AMD market either as a monotherapy or in combination with the current standard of care, QLT/Novartis Ophthalmics' Visudyne (verteporfin/photodynamic therapy). Lucentis will command a 52% share of the total AMD market in 2010 and a 62% share in 2015 in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom. The report also finds that an increasing aging population and earlier awareness of the disease will drive a threefold increase in the drug-treated population from 2005 to 2015.

"Additionally, more aggressive education, awareness, and screening could significantly increase the number of patients receiving drug treatment beyond this estimate," said Regina Cebula, analyst at Decision Resources, Inc. "We forecast dramatic 23% annual growth in the AMD drug treatment market from 2005 through 2010 as a result of more widespread use of premium-priced emerging therapies, including Lucentis, as well as an increase in the number of patients being diagnosed and treated. Thereafter, annual market growth will level off to 8% through 2015."

About Age-Related Macular Degeneration

Age-related macular degeneration, an under-treated vision-threatening disease affecting people over 50 years of age, will directly impact a significant segment of the increasing aging population. Treatment of the disease represents considerable commercial potential for developers of innovative drug therapies. In 2005, the total prevalent population exceeded 3.8 million cases in the world's major pharmaceutical markets.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Standoff Between HealthONE and UnitedHealthcare of Colorado Precursor of Future Struggles in Denver's Healthcare Market

View Now